Christopher Kenney

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
    Expert Rev Neurother 6:7-17. 2006
  2. ncbi Distinguishing psychogenic and essential tremor
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, United States
    J Neurol Sci 263:94-9. 2007
  3. ncbi Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    Expert Opin Pharmacother 8:1329-35. 2007
  4. ncbi Botulinum toxin in the treatment of blepharospasm and hemifacial spasm
    C Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neural Transm 115:585-91. 2008
  5. ncbi Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurosurg 106:621-5. 2007
  6. ncbi Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:193-7. 2007
  7. ncbi Autopsy-proven Huntington's disease with 29 trinucleotide repeats
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:127-30. 2007
  8. ncbi Short-term effects of tetrabenazine on chorea associated with Huntington's disease
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:10-3. 2007
  9. ncbi Is history of depression a contraindication to treatment with tetrabenazine?
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Neuropharmacol 29:259-64. 2006
  10. ncbi Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report
    Alan Diamond
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurosurg 107:1036-8. 2007

Detail Information

Publications18

  1. ncbi Tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA
    Expert Rev Neurother 6:7-17. 2006
    ....
  2. ncbi Distinguishing psychogenic and essential tremor
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, United States
    J Neurol Sci 263:94-9. 2007
    ..In conclusion, a history of tremor with sudden onset and spontaneous remissions along with distractibility and suggestibility on examination are good predictors of PT and help differentiate it from ET...
  3. ncbi Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    Expert Opin Pharmacother 8:1329-35. 2007
    ..Advantages over existing dopamine agonists include once-daily administration, absence of food interactions, maintenance of stable plasma levels and utility in patients with swallowing difficulties...
  4. ncbi Botulinum toxin in the treatment of blepharospasm and hemifacial spasm
    C Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neural Transm 115:585-91. 2008
    ..This article summarizes the existing medical literature which indicates that botulinum toxin is the treatment of choice for blepharospasm and hemifacial spasm...
  5. ncbi Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurosurg 106:621-5. 2007
    ..The object of this study was to assess the long-term safety of deep brain stimulation (DBS) in a large population of patients with a variety of movement disorders...
  6. ncbi Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:193-7. 2007
    ..6%), and akathisia (7.6%). Comparison of log-likelihood ratios revealed that age was a reliable predictor of Parkinsonism (P < 0.0001). TBZ is a safe and effective drug for the long-term treatment of hyperkinetic movement disorders...
  7. ncbi Autopsy-proven Huntington's disease with 29 trinucleotide repeats
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:127-30. 2007
    ..A minimum of 36 CAG repeats is usually reported in patients with clinical features of HD; 30 to 35 repeats represent an intermediate range. Here we report a 65-year-old male with autopsy-proven HD and 29 CAG repeats...
  8. ncbi Short-term effects of tetrabenazine on chorea associated with Huntington's disease
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 22:10-3. 2007
    ..2 hours to a maximum of 8.1 hours (mean = 5.4 +/- 1.3). No patient experienced an adverse event related to TBZ or its withdrawal. During short-term follow-up after a single dose, TBZ improves chorea for approximately 5 hours...
  9. ncbi Is history of depression a contraindication to treatment with tetrabenazine?
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    Clin Neuropharmacol 29:259-64. 2006
    ..To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom...
  10. ncbi Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report
    Alan Diamond
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Neurosurg 107:1036-8. 2007
    ..Although a rare complication, hypothalamic dysfunction may occur as a stimulation-related side effect of Vim-DBS...
  11. doi Relationship between various clinical outcome assessments in patients with blepharospasm
    Joseph Jankovic
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 24:407-13. 2009
    ..Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials...
  12. doi Metoclopramide, an increasingly recognized cause of tardive dyskinesia
    Christopher Kenney
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Houston, TX 77030, USA
    J Clin Pharmacol 48:379-84. 2008
  13. doi Bilateral pedunculopontine nuclei strokes presenting as freezing of gait
    Sheng Han Kuo
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas 77030, USA
    Mov Disord 23:616-9. 2008
    ..We report a patient with bilateral PPN infarcts whose dominant clinical feature was freezing of gait, thus providing evidence that PPN is involved in human locomotion and that damage to the PPN may lead to abnormal gait...
  14. doi Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial
    Joseph M Ferrara
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA
    J Neurol Sci 285:195-7. 2009
    ..Adverse events were similar in frequency to previously published studies of PGB, the most common being drowsiness and dizziness...
  15. ncbi Tourette's syndrome
    Christopher Kenney
    Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA
    Am Fam Physician 77:651-8. 2008
    ..Appropriate diagnosis and treatment can substantially improve quality of life and psychosocial functioning in affected children...
  16. ncbi Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy
    Alan Diamond
    Parkinson s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA
    Mov Disord 21:1273-5. 2006
    ..If verified by controlled clinical trials, this observation may provide insights into the pathophysiology of tics and may lead to a novel therapy for patients with severe TS...
  17. pmc CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases
    Jing Zhang
    Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA
    Am J Clin Pathol 129:526-9. 2008
    ..This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD...
  18. ncbi Role of deep brain stimulation targeted to the pedunculopontine nucleus in Parkinson's disease
    Christopher Kenney
    Expert Rev Neurother 7:585-9. 2007